Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia

scientific article published on 27 October 2017

Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3390/IJMS18112259
P932PMC publication ID5713229
P698PubMed publication ID29077054

P50authorPeter G. SchultzQ899840
P2093author name stringEduardo Laborda
Travis S Young
Ashley K Woods
Xinxin Wang
David T Rodgers
Chan Hyuk Kim
Herlinda Quirino
Eric N Hampton
Sida Shao
Magdalena Mazagova
P2860cites workTreatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1.Q40135347
Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemiaQ40314122
Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironmentQ41873361
Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancerQ42157682
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivoQ42938990
Modulation of human neutrophil survival and antigen expression by activated CD4+ and CD8+ T cells.Q45256536
Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathwaysQ77137106
The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigensQ81663230
Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemiaQ83030425
Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.Q34329186
C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemiaQ34368778
The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cellsQ34645694
Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.Q35146288
Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemiaQ35591409
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapyQ36328394
The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.Q36408432
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignanciesQ36551673
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.Q37117781
Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cellsQ37244349
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.Q37272020
Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practiceQ37554901
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cellsQ37697847
Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemiaQ38972314
Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.Q39026376
Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17--a new mechanism of impaired antitumor immunityQ39026688
Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human StudiesQ39038206
Myeloid leukemia cells with a B7-2(+) subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands.Q39240280
Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemiaQ39817951
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue11
P407language of work or nameEnglishQ1860
P577publication date2017-10-27
P1433published inInternational Journal of Molecular SciencesQ3153277
P1476titleDevelopment of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia
P478volume18

Reverse relations

cites work (P2860)
Q90413936A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
Q100958764A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells
Q55292778Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?
Q103728286Autologous non-human primate model for safety assessment of piggyBac transposon-mediated chimeric antigen receptor T cells on granulocyte-macrophage colony-stimulating factor receptor
Q64245424Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
Q57898900Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
Q97538364Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia
Q89805236Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond
Q93017003Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
Q48091597Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology.
Q64094664Targeting CLL-1 for acute myeloid leukemia therapy

Search more.